The guidance beat matters because H&R Block operates in a business that Wall Street often treats as a slow, predictable cash generator rather than a growth story — which makes an upside surprise of this magnitude particularly notable. The projected EPS range implies double-digit percentage growth versus current-year expectations, suggesting management sees continued momentum in both its core tax-filing business and its expanding suite of financial products, including small-business services and Block Advisors. Investors have increasingly rewarded companies that can show durable earnings growth without relying on speculative AI or crypto narratives, and H&R Block’s forecast fits that mold squarely.

For portfolio construction, H&R Block represents a case study in why guidance quality can matter more than the headline print. A 2027 forecast issued more than a year in advance, and one that beats consensus by a wide margin, tends to reflect real visibility into contract renewals, pricing power, and cost discipline rather than one-off tailwinds. Investors looking for ballast in a market dominated by high-multiple AI names may want to take a fresh look at steady, cash-generative businesses like this one — particularly if the stock’s post-earnings pop settles into a valuation that still looks reasonable relative to the raised outlook. Kontoor Brands and Cava Group posted similar beat-and-raise setups this week, a reminder that solid execution stories are still getting rewarded even as headlines stay fixated on AI infrastructure spending.

The numbers behind the guidance raise tell an even stronger story. Year-to-date bookings have already reached approximately $81 million, including a major new agreement with Oracle, and management said it expects to book at least $120 million for the full year. Remaining performance obligations stood at roughly $74 million at quarter-end, a figure CFO Nitesh Sharan said should grow meaningfully once post-quarter bookings are included. Quantinuum ended the quarter with about $2.1 billion in cash — a substantial war chest — even as it reported a $596.5 million GAAP net loss, largely tied to one-time IPO-related stock compensation rather than ongoing operations. The company is also progressing toward its next-generation Sol system, targeted for a 2027 launch, and a longer-term fault-tolerant Apollo system planned for 2029.

For investors, Quantinuum is a high-risk, high-reward bet on quantum computing moving from lab curiosity to commercial infrastructure. The Oracle and Hewlett Packard Enterprise partnerships signal that large cloud and enterprise players are already integrating quantum tools into AI and high-performance computing workflows — a validation signal that matters more than any single quarter’s revenue number. Management’s call for more than 100% revenue growth in 2027 versus 2026 guidance suggests the company sees an inflection point ahead. That said, this remains an early-stage, cash-burning business trading on a growth narrative; investors should size any position accordingly and watch bookings momentum, not just revenue, as the real signal of commercial traction.

Peltz’s involvement with Wendy’s dates back to 2005, when Trian first launched an activist campaign at the company. Trian executive Peter May and Bradley Peltz, Nelson Peltz’s son, currently sit on Wendy’s board. In a February SEC filing, Trian called Wendy’s shares undervalued and said it was reaching out to potential co-investors about strategic alternatives. The Financial Times separately reported in May that Trian had discussed take-private financing with Middle East-based investors. Wendy’s stock has lagged the broader restaurant sector this year as same-store sales growth stayed sluggish and investors questioned the company’s turnaround under intensifying fast-food competition, compressing its valuation to levels that make a buyout more financially attractive for Peltz.

For investors, this is a classic activist-driven special situation. If Trian formalizes an offer in the coming weeks, Wendy’s independent board would need to evaluate it against a potential broader auction, which could invite competing bids and further upside. Shareholders holding WEN should watch for an actual bid filing rather than trading purely on rumor — deals like this can take months and sometimes fall apart entirely, as Trian’s own 2022 exploration of a similar deal did. Still, the stock’s depressed valuation heading into this report, combined with a credible, deeply entrenched activist already on the board, makes Wendy’s a name worth tracking closely for M&A-driven volatility in the weeks ahead.

Lululemon shares are down more than 40% year-to-date after fiscal Q1 revenue grew just 4% and North American sales stayed soft. But the bull case has real numbers behind it — China revenue grew 23% year-over-year in constant currency, international revenue overall rose 16%, and the company carries no debt while sitting on $1.51 billion in cash. The stock now trades at just 10.5 times forward earnings, a multi-year low against a five-year average closer to 29 times, with a new CEO set to take over soon. MercadoLibre tells a different story: Latin America’s largest e-commerce marketplace posted 50% year-over-year revenue growth to $10.2 billion in Q2, its fastest pace in four years, yet shares fell 6% after the print because operating margin dropped 550 basis points. Hedge fund interest has cooled slightly on both names — LULU saw hedge fund holders drop and MELI lost 11 funds quarter-over-quarter — even as Burry moves in.

For retail investors, this is a classic value-versus-momentum split. Burry is betting the market has overcorrected on both names, pricing in permanent damage where the underlying growth story — China expansion for Lululemon, marketplace scale for MercadoLibre — is still intact. The risk is real: apparel names that lose momentum can stay cheap for years, and margin compression at MercadoLibre could persist if competition in Latin American e-commerce keeps intensifying. If you’re considering following Burry into either name, treat the low multiples as a starting point for research, not a guarantee — and watch the next earnings print closely for signs the margin and growth trends are stabilizing.

The numbers behind the pop are striking. CoreWeave’s revenue backlog stood at $104 billion as of June 30 — and that figure doesn’t even include $25 billion in new customer commitments signed for the third quarter. Meta alone added $21 billion in additional spending with CoreWeave during the period, while Jane Street committed $1 billion in strategic investment. The company isn’t profitable yet — operating expenses more than doubled to $2.6 billion, leaving an operating loss of $49 million versus a profit a year ago — but full-year guidance now calls for $12.4 billion to $13.2 billion in revenue. The AI infrastructure boom is lifting the whole neocloud category: Nebius jumped 17% on a 514% revenue surge, and Supermicro rose 9% after reporting more than $60 billion in new orders.

For investors, CoreWeave is becoming the clearest bellwether for how much runway is left in the AI infrastructure trade. A $104 billion backlog signals demand isn’t slowing, but the widening operating losses are a reminder that these gains come with real cash burn. If you’re playing this theme, watch margin trends more than revenue growth from here — that’s where the next leg of the story will be written. Diversifying across neocloud names like Nebius and hardware suppliers like Supermicro can also spread out the risk from betting on any single AI infrastructure stock.

The details matter here. Energy prices fell another 1.5% in July after a 5.7% drop in June, even though energy costs are still up 14.7% year-over-year following the spike tied to the Iran conflict earlier this year. Shelter costs, which have been the stickiest part of the inflation picture, rose just 0.1% but still accounted for roughly two-thirds of the headline increase. Airline fares jumped 2.2% and medical care rose 0.4%, showing pockets of the economy still running hot even as the broader trend cools. Traders responded fast: the CME Group’s FedWatch tool now puts the odds of a September rate hike at just 42%, down sharply from levels seen a week ago, with the market instead pricing in a possible move in October or December.

For investors, this is a green light to lean back into rate-sensitive names. Growth stocks, small caps, and REITs tend to benefit when hike odds fade, and Wednesday’s futures pop reflected exactly that rotation. Keep an eye on the shelter and energy components in next month’s report — if either reaccelerates, especially with Middle East tensions still simmering, the Fed’s hold could get shakier fast. Until then, this print buys the market room to run.

Lockheed is responding by tripling PAC-3 MSE production capacity by the end of 2030 and growing its Camden, Arkansas workforce from 1,200 to roughly 1,850 employees, backed by $8-9 billion in facility investment through 2030. This marks Lockheed’s second major multiyear award under the Pentagon’s Acquisition Transformation Strategy, following a $35 billion THAAD contract earlier this year. The company generated $75.1 billion in FY2025 revenue, up 5.7%, with $6.9 billion in free cash flow. Hedge fund ownership climbed from 59 funds to 83 last quarter, while short interest sits at a thin 1.62% of float — signs of rising institutional conviction. Yet the stock’s forward P/E of 19.84 remains an ordinary multiple given the fresh backlog, suggesting the market hasn’t fully priced in the order flow.

Investors should weigh the bull case against real concentration risk. Roughly 72% of Lockheed’s 2025 sales came from the U.S. government, and the F-35 program alone makes up about 27% of revenue — a level of dependency that magnifies any shift in Washington’s spending priorities. Debt to equity sits near 3.2x, thinner than investors might expect for a company this size. Still, with a seven-year contract locked in, a depleted global stockpile, and officials describing wartime urgency around production, Lockheed offers a defense-sector name backed by concrete, multiyear revenue visibility — a rare combination in a market still guessing at AI valuations.

The Anthropic agreement stacks on top of Riot’s existing deal with AMD, giving the company what analyst Michael Donovan at Compass Point called a “two-tenant campus carrying $9.8 billion of contracted data center revenue.” That’s a meaningful shift in how the market should value Riot. Bitcoin mining stocks used to trade as leveraged plays on crypto prices, but with a prolonged slump in cryptocurrency and surging AI power demand, miners with data center assets and energy contracts are increasingly valued as infrastructure landlords rather than coin producers. Cipher Mining, Hut 8, and TeraWulf have already made similar pivots, while Riot, Mara Holdings, and CleanSpark had largely stayed pure-play miners — until now.

The takeaway for investors: power and data center capacity, not bitcoin price action, is becoming the real value driver for miners. AI companies all need the same scarce inputs — electricity, compute capacity, and physical facilities — regardless of which model or application wins the broader AI race, so this kind of infrastructure deal offers exposure without picking a single AI winner. For investors who’ve watched bitcoin miner stocks whipsaw with crypto prices, Riot’s move signals a business model transition worth tracking closely — and a reason to look at contracted, multi-year revenue figures rather than daily bitcoin headlines when evaluating these names.

The fundamentals behind that recovery are hard to ignore. MP’s Mountain Pass facility in California accounts for more than 10% of global rare earth supply, and the Pentagon backed the company with a $400 million investment, a 15% equity stake, and a 10-year offtake agreement guaranteeing a price floor of $110 per kilogram — insulation from any price war China might try to engineer. Apple signed a $500 million deal for American-made magnets tied to a new recycling program, General Motors has a standing supply agreement for EV traction motors, and a joint venture with Saudi Arabia’s state mining company adds a second refining leg outside China entirely. First-quarter 2026 revenue jumped 49% year-over-year to $90.6 million, beating Wall Street estimates as commercial magnet shipments began scaling. New defense acquisition rules require contractors to phase out Chinese-origin magnets by January 2027, giving MP a hard regulatory tailwind through the rest of the decade.

For investors, this is a supply-chain bottleneck story with government money behind it. Rare earth magnets sit inside humanoid robots, EV motors, satellite reaction wheels, chip-fab wafer handlers, and guided munitions — demand that analysts expect to roughly triple by 2040. MP is the only pure-play way to bet on that shift domestically, and the price floor, equity backing, and blue-chip customer list give the stock a downside cushion that’s rare in a commodity-linked business. Investors bullish on the “physical AI” buildout — robotics, EVs, defense — should treat any pullback in MP shares as a chance to build a position, not a reason to walk away.

The competitive dynamics are worth tracking closely. Foundayo launched in the U.S. back in April and generated $98 million in second-quarter sales — a respectable start, but notably slower than Wegovy’s pill uptake, according to Lilly CEO David Ricks, who told CNBC in April the drug simply needs more time to establish itself with doctors and patients. Lilly is leaning on a key differentiator: unlike Wegovy, which requires patients to take it first thing in the morning with water and no food for 30 minutes, Foundayo is a small-molecule drug that can be taken without those food restrictions. Novo, meanwhile, is showing strong momentum of its own — CEO Mike Doustdar said roughly 300,000 UK patients started on the Wegovy pill within its first three weeks of availability, and he’s betting the oral pill market could eventually rival injectables in size. Foundayo will still need a cost-effectiveness review from the UK’s NICE body before it’s available through the National Health Service, a hurdle that could delay broader uptake.

For investors in either name, this is a market-share story more than a binary win-or-lose event. Both companies argue oral pills are expanding the overall weight-loss market rather than just cannibalizing injectable sales, which is bullish for total addressable market size across the sector. Lilly shareholders should watch U.S. prescription trends for Foundayo as the best leading indicator of whether its ease-of-use pitch is resonating, while Novo holders should track UK reimbursement decisions as a proxy for how fast reimbursement-dependent, international markets adopt these pills. Either way, the GLP-1 pill category looks like it has room to grow for both players.